文献速递肥胖与代谢综合征

利拉鲁肽用于Prader-Willi综合征合并肥胖儿童和青少年的体重管理

Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项多中心、52周、安慰剂对照试验纳入31名12-17岁青少年和24名6-11岁儿童(均患Prader-Willi综合征合并肥胖),随机2:1接受利拉鲁肽3.0 mg或安慰剂16周双盲治疗,之后安慰剂组停药,利拉鲁肽持续至52周,所有患者均接受结构化饮食和运动计划。主要终点BMI标准差评分从基线至16周和52周的变化在青少年和儿童中两组均无显著差异。青少年中利拉鲁肽组52周时贪食总分和驱动力评分低于无治疗组,最常见不良事件为胃肠道疾病。

要点

  • 利拉鲁肽3.0 mg治疗16周和52周后BMI标准差评分变化在青少年和儿童中均与安慰剂/无治疗无显著差异。
  • 青少年中利拉鲁肽组52周时贪食总分和驱动力评分低于无治疗组。
  • 利拉鲁肽最常见不良事件为胃肠道疾病。

核心结论

  • 虽然共同主要终点未达到,但青少年中贪食总分和驱动力评分的变化值得对利拉鲁肽在该人群中进行进一步研究。

研究设计与样本

  • 多中心、52周、安慰剂对照试验,含16周双盲期;纳入青少年31名(12-17岁,Tanner分期2-5)和儿童24名(6-11岁,Tanner分期<2),均患Prader-Willi综合征合并肥胖。
  • 患者按2:1随机接受利拉鲁肽3.0 mg(或最大耐受剂量)或安慰剂治疗16周,之后安慰剂停用,利拉鲁肽继续至52周;所有患者全程遵循结构化饮食和运动计划。

主要发现

  • BMI标准差评分从基线至16周和52周的变化在青少年中两组无显著差异(估计治疗差异:第16周-0.07,第52周-0.14),在儿童中亦无显著差异(分别为-0.06和-0.07)。
  • 其他体重相关参数的两组间变化均无显著差异。
  • 第52周时,青少年中利拉鲁肽治疗组贪食总分和驱动力评分低于无治疗组。
  • 利拉鲁肽最常见的不良事件为胃肠道疾病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prader-Willi syndrome (PWS) is characterized by lack of appetite control and hyperphagia, leading to obesity. Pharmacological options for weight management are needed. OBJECTIVE: To determine whether liraglutide treatment for weight management is superior to placebo/no treatment in pediatric individuals with PWS. METHODS: This was a multicenter, 52-week, placebo-controlled trial with a 16-week double-blinded period. Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included. Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped. Liraglutide was continued for 52 weeks. All patients followed a structured diet and exercise program throughout the trial. The coprimary endpoints were change in body mass index (BMI) standard deviation score (SDS) from baseline to 16 and 52 weeks. Secondary endpoints included other weight-related parameters, hyperphagia, and safety. RESULTS: Change in BMI SDS from baseline to weeks 16 and 52 was not significantly different between treatments in adolescents (estimated treatment difference: -0.07 at week 16 and -0.14 at week 52) and children (-0.06 and -0.07, respectively). Changes in other weight-related parameters between treatments were not significant. At week 52, hyperphagia total and drive scores were lower in adolescents treated with liraglutide vs no treatment. The most common adverse events with liraglutide were gastrointestinal disorders. CONCLUSION: Although the coprimary endpoints were not met, changes in hyperphagia total and drive scores in adolescents warrant further studies on liraglutide in this population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Diene G, Angulo M, Hale PM, et al. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab. 2022. PMID: 36181471. doi:10.1210/clinem/dgac549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。